Zhengye Biotechnology Holding Limited (ZYBT) Income Statement
ZYBT 2025 at a glance
Fiscal year ended December 31, 2025 · Chinese yuanZYBT revenue and net income
Where ZYBT's revenue goes
2025Each bar shows an amount and its share of revenue. ZYBT kept −60.0% of revenue as net income.
ZYBT profit margins
ZYBT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −37.6% | −23.5% | — | — |
| Gross profit | −73.9% | −46.2% | — | — |
| Operating income | −497.5% | — | — | — |
| Net income | −717.0% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ZYBT income statement in Chinese yuan
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | CN¥116.4M | CN¥186.4M | CN¥211.7M | CN¥260.3M | CN¥214.1M |
| Cost of revenue | CN¥92.5M | CN¥95.1M | CN¥81.8M | CN¥106.8M | CN¥88.7M |
| Gross profit | CN¥23.9M | CN¥91.3M | CN¥129.9M | CN¥153.5M | CN¥125.4M |
| Research & development | CN¥18.0M | CN¥12.8M | CN¥11.9M | CN¥13.4M | CN¥11.4M |
| Sales, general & admin | CN¥74.9M | CN¥63.8M | CN¥66.6M | CN¥63.6M | CN¥58.2M |
| Total operating expenses | CN¥92.1M | CN¥169.2M | CN¥84.9M | CN¥87.7M | CN¥73.0M |
| Operating income | −CN¥68.3M | CN¥17.2M | CN¥45.0M | CN¥65.8M | CN¥52.4M |
| Interest income | CN¥96,000 | CN¥231,000 | CN¥312,000 | CN¥114,000 | CN¥112,000 |
| Interest expense | CN¥3.4M | CN¥4.0M | CN¥4.4M | CN¥2.8M | CN¥1.0M |
| Income before taxes | −CN¥71.9M | CN¥14.4M | CN¥43.8M | CN¥63.9M | CN¥53.1M |
| Income taxes | CN¥11.1M | — | CN¥6.3M | CN¥8.2M | CN¥6.6M |
| Net income | −CN¥69.8M | CN¥11.3M | CN¥31.5M | CN¥46.7M | CN¥39.0M |
| EBITDA | −CN¥42.5M | CN¥42.6M | CN¥72.1M | CN¥85.6M | CN¥70.1M |
| Gross margin | 20.5% | 49.0% | 61.4% | 59.0% | 58.6% |
| Operating margin | −58.7% | 9.2% | 21.3% | 25.3% | 24.5% |
| Net margin | −60.0% | 6.1% | 14.9% | 18.0% | 18.2% |
| Mar '26 | Sep '25 | Mar '25 | |
|---|---|---|---|
| Revenue | CN¥53.0M | CN¥27.0M | CN¥31.2M |
| Cost of revenue | CN¥48.6M | CN¥24.8M | CN¥21.5M |
| Gross profit | CN¥4.4M | CN¥2.2M | CN¥9.7M |
| Research & development | CN¥8.9M | CN¥4.5M | CN¥4.5M |
| Sales, general & admin | — | CN¥18.5M | CN¥20.0M |
| Total operating expenses | CN¥45.3M | CN¥23.1M | CN¥24.1M |
| Operating income | −CN¥40.9M | −CN¥20.8M | −CN¥14.4M |
| Interest expense | CN¥1.6M | CN¥812,000 | — |
| Income before taxes | −CN¥40.2M | −CN¥20.5M | −CN¥15.4M |
| Income taxes | CN¥16.1M | CN¥8.2M | CN¥2.7M |
| Net income | −CN¥47.2M | −CN¥24.1M | −CN¥10.8M |
| EBITDA | −CN¥27.4M | −CN¥14.0M | −CN¥8.3M |
| Gross margin | 8.3% | 8.3% | 31.1% |
| Operating margin | −77.0% | −77.0% | −46.3% |
| Net margin | −89.0% | −89.0% | −34.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in Chinese yuan as reported in ZYBT's financial statements (latest annual report filed April 28, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ZYBT financial results
In fiscal year 2025 (ended December 31, 2025), Zhengye Biotechnology reported revenue of CN¥116.4 million, down 37.6% from the year before. It had a net loss of CN¥69.8 million, a net profit margin of −60.0%. Figures are in Chinese yuan, the currency of its financial statements.
See the ZYBT stock overview for the latest quote and news, or the ZYBT chart for price history and technical indicators.
ZYBT income statement FAQ
What is Zhengye Biotechnology's annual revenue?
Zhengye Biotechnology reported total revenue of CN¥116.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 37.6% from CN¥186.4 million the previous year.
Is Zhengye Biotechnology profitable?
No. Zhengye Biotechnology reported a net loss of CN¥69.8 million in fiscal 2025, a net profit margin of −60.0%; its operating margin was −58.7%.
What is Zhengye Biotechnology's gross margin?
Zhengye Biotechnology's gross margin was 20.5% in fiscal 2025: for every $100 of revenue, Zhengye Biotechnology kept $21 after the direct cost of its products and services.
How much does Zhengye Biotechnology spend on research and development?
Zhengye Biotechnology spent CN¥18.0 million on research and development in fiscal 2025, 15.5% of revenue.
When does Zhengye Biotechnology's fiscal year end?
Zhengye Biotechnology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 28, 2026.